Content
Search
Navigation
Sitemap

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

News

Show

Sustainability
Financial
Operating News

news from

all companies
Syncona
all Cell therapy companies
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Neogene Therapeutics
Clade Therapeutics
all Gene therapy companies
Freeline Therapeutics
AGTC
SwanBio Therapeutics
Purespring Therapeutics
all Biologics companies
Anaveon
all Small molecule companies
OMass Therapeutics
Kesmalea Therapeutics

29.11.22

Freeline Receives Approval to Transfer to Nasdaq Capital Market

Operating News
Gene therapy
Freeline Therapeutics

24.11.22

Purespring Chief Executive Officer Richard Francis appointed Chief Executive Officer of Teva Pharmaceutical Industries Ltd

Operating News
Gene therapy
Purespring Therapeutics

15.11.22

Freeline Reports Third Quarter 2022 Financial Results and Corporate Update

Operating News
Gene therapy
Freeline Therapeutics

05.10.22

Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Operating News
Gene therapy
Freeline Therapeutics

04.10.22

Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease

Operating News
Gene therapy
Freeline Therapeutics

07.09.22

Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Operating News
Gene therapy
Freeline Therapeutics

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

RNS alerts
Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR

contact@synconaltd.com

About us
Our people
Portfolio
Sustainability
News and Insights
Investors
Contact

Copyright © Syncona 2022
Accessibility
Privacy & cookies
Employee privacy notice
Third party privacy notice
Regulatory publications
Modern Slavery Statement

Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

Designed & built by SampsonMay

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

GBX 182.00

Change: +3.00 (+1.68%)

Search

Search